Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bone Marrow Supernatant IL-6 as a Predictor of Chemotherapy Sensitivity in AML Patients

NCT06486350 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT06486350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06486350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bone Marrow Supernatant IL-6 as a Predictor of Chemotherapy Sensitivity in AML Patients
Lead sponsor
Fujian Medical University Union Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2023
Completion date
June 30, 2025
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult